Loading
DHODH is an enzyme cells need to make pyrimidines, the building blocks of DNA and RNA. Blocking it pushed immature leukaemia cells to mature in mouse studies, and a DHODH inhibitor is in an early trial in solid tumours and lymphoma. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Enzyme that uses a quinone as electron acceptor to make orotate, required for UMP biosynthesis by the de novo pathway (UniProt Q02127).
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1 | Recruiting | A Phase 1, Open-label, Dose-escalation and Expansion, First-in-human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JBZ-001, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Patients With Advanced Solid and Hematological Malignancies | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"DHODH" OR ABSTRACT:"DHODH" OR TITLE:"dihydroorotate dehydrogenase" OR ABSTRACT:"dihydroorotate dehydrogenase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DHODH, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/dhodh.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/dhodh.json. Licence CC BY-NC 4.0.